DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

ABSTRACT:

Background

The efficacy of current influenza vaccines is limited in vulnerable populations. DNA vaccines can be produced rapidly, and may offer a potential strategy to improve vaccine immunogenicity, indicated by studies with H5 influenza DNA vaccine prime followed by inactivated vaccine boost.

Methods

Four sites enrolled healthy adults, randomized to receive 2011/12 seasonal influenza DNA vaccine prime (n=65) or phosphate buffered saline (PBS) (n=66) administered intramuscularly with Biojector. All subjects received the 2012/13 seasonal inactivated influenza vaccine, trivalent (IIV3) 36 weeks after the priming injection. Vaccine safety and tolerability was the primary objective and measurement of antibody response by hemagglutination inhibition (HAI) was the secondary objec

SUBMITTER: Ledgerwood JE 

PROVIDER: S-EPMC4423975 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature